Hondo

[Hondo @JimTom44]

@doccjc62 $rdgl One step at a time. Takes much longer than anyone thought but they keep moving forward. Check another box!

[Hondo @JimTom44]

$rdgl They just keep on checking boxes! "Vivos will immediately apply for an amendment to add RadioGel® to the license. This amendment will support clinical trials in the United States and, as necessary, internationally." https://t.co/BURkzdiqVf

[Hondo @JimTom44]

$rdgl Agree. With the professional guidance of John Smith and his team at Hogan Lovells, odds are greatly increased. Best of luck to @VivosIncUSA and all shareholders.

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL Still under the radar, but 25 days max may change all of that. Bring on the IDE decision.

[Hondo @JimTom44]

$rdgl From the PR: The Early Feasibility IDE application, developed with expert regulatory guidance from our experienced IDE approval specialists, reflects Vivos’ iterative engagement with the FDA" Experts on board driving this process. https://t.co/HsArQYyz5x

[Hondo @JimTom44]

$rdgl https://t.co/MBWniMx3WL

[Albino Skunk @BillH480045]

@RDGLinvestors

Did we miss this little gem hidden in there $Radiogel website

https://t.co/eca42d7L8l

[Hondo @JimTom44]

$rdgl

[RDGL INVESTORS GROUP @RDGLinvestors]

1/7
PrecisionGel: A Platform Beyond RadioGel?
Vivos Inc. ($RDGL) just dropped new data on PrecisionGel. While everyone’s talking oncology, this could be the start of a versatile controlled-release delivery platform with huge potential across many medical fields.
Educational thread 👇

[Hondo @JimTom44]

@BradWeeks0331 @VivosIncUSA $rdgl How is the Society of Nuclear Medicine Annual Meeting going? Photos and/or updates would be appreciated. Thank you. https://t.co/KGhG0i5lVR

[Hondo @JimTom44]

$rdgl
https://t.co/7vFinohSEI

[Hondo @JimTom44]

@IsoPetForCancer $rdgl This should be front and center on the front page of https://t.co/QnEthlUR6L with a link in your tweet. https://t.co/7vFinohSEI

[Hondo @JimTom44]

@IsoPetForCancer @VivosIncUSA @BradWeeks0331 Please provide a link. It's much easier for people.

[Hondo @JimTom44]

$rdgl First step IDE approval with the help of Dr. John J. Smith, M.D., J.D. and his team at Hogan Lovells. After approval, on to Mayo human trials. Then.... on to taking some of this market. @VivosIncUSA @BradWeeks0331

[Albino Skunk @BillH480045]

@RDGLinvestors @VivosIncUSA @RadioGel Billions are pouring into precision oncology and targeted solid tumor therapies. RadioGel from Vivos Inc. may offer a different approach: localized Y-90 radiation delivered directly into tumors with minimal migration outside the treatment area. $RDGL #Biotech #Cancer

[Hondo @JimTom44]

$rdgl @VivosIncUSA are working towards and getting primed to take some of that market. @BradWeeks0331

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL (Vivos Inc.) Perfectly Positioned as Solid Tumor Treatment Race Accelerates in Multi-Billion Dollar Oncology Boom.
@VivosIncUSA @RadioGel

https://t.co/31ywohJjt7

[Hondo @JimTom44]

$rdgl Thankful they brought in Dr. John J. Smith, M.D., J.D., and his team at Hogan Lovells as the company’s lead regulatory advisors for its FDA Investigational Device Exemption (IDE) submission for RadioGel®.
With approval, @VivosIncUSA rockets to a whole new level.

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL MAY BE ONE OF THE MOST OVERLOOKED MICROCAP ONCOLOGY PLAYS RIGHT NOW

$RDGL is trading around $0.065 (~$32M market cap), and looks significantly undervalued relative to its pipeline and catalysts.

Key points:

• RadioGel – targeted radiotherapy platform for solid tumors

• Upcoming IDE submission – major regulatory milestone

• Mayo Clinic involvement for future human trials

• International clinical development efforts in India supporting broader oncology pathway expansion

• IsoPet – veterinary oncology business with strong year-over-year growth in treated cases and expanding adoption

• PrecisionGel – next-gen platform with licensing / partnership opportunities

Multiple shots on goal across human + veterinary oncology, with several near-term catalysts ahead.

Not financial advice ,just a small-cap biotech worth watching closely.

[Hondo @JimTom44]

$rdgl They have a lot going on behind the scene. IDE #1, IsoPet is sneaky huge, PrecisionGel.....and more I'm sure. @VivosIncUSA

[Alpha167🇺🇸 @ClearUTL]

This will be a great addition to Vivos Inc bag of tools!! $$$$

[Hondo @JimTom44]

April 30 IDE update: "We remain highly confident in the quality and completeness of our application and anticipate submitting in the near term with no substantial delay expected.".... On May 11 @VivosIncUSA CEO buys 150,000 shares. $rdgl https://t.co/IcfDiT9eNM

[Hondo @JimTom44]

$rdgl "In addition, Vivos is preparing to bring online its new in-house production facility, which is expected to deliver significant improvements in manufacturing efficiency and support scaled treatment of a growing number of patients." https://t.co/lM5UVqx2d4

[Hondo @JimTom44]

$rdgl Yes bullish. Particularly with all the activity lately. @VivosIncUSA

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL CEO Dr Korenko just purchased 150,000 shares on the open market . Bullish !

https://t.co/mBuc7mXIMY

[Hondo @JimTom44]

@VivosIncUSA CEO buys another 150,000 shares at .0618. Nice to see. $rdgl https://t.co/IcfDiT9eNM

[Hondo @JimTom44]

$rdgl

[Vivos Inc. @VivosIncUSA]

Vivos Inc. is pleased to announce the completed enrollment in a 20 patient clinical study for our IsoPet® Postoperative Precision Radionuclide Therapy for Incomplete Tumor Resection. To read the full statement visit https://t.co/XTEjJBqPWS

[Hondo @JimTom44]

Anu! Great story. Bless this dog, his family and @IsoPetForCancer. We're hearing more and more stories like this. 100+ successful treatments and counting. $rdgl